Bon Natural Life (BON) Competitors $1.47 +0.02 (+1.19%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends BON vs. CDT, OBSV, CERO, SNGX, COEP, NLSP, EVOK, EYEN, ADIL, and GRIShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Conduit Pharmaceuticals (CDT), ObsEva (OBSV), CERo Therapeutics (CERO), Soligenix (SNGX), Coeptis Therapeutics (COEP), NLS Pharmaceutics (NLSP), Evoke Pharma (EVOK), Eyenovia (EYEN), Adial Pharmaceuticals (ADIL), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Conduit Pharmaceuticals ObsEva CERo Therapeutics Soligenix Coeptis Therapeutics NLS Pharmaceutics Evoke Pharma Eyenovia Adial Pharmaceuticals GRI Bio Bon Natural Life (NYSE:BON) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap consumer discretionary companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations. Does the media refer more to BON or CDT? In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Conduit Pharmaceuticals and 0 mentions for Bon Natural Life. Conduit Pharmaceuticals' average media sentiment score of 0.29 beat Bon Natural Life's score of 0.00 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Bon Natural Life Neutral Conduit Pharmaceuticals Neutral Do analysts recommend BON or CDT? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has stronger earnings & valuation, BON or CDT? Bon Natural Life has higher revenue and earnings than Conduit Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBon Natural Life$25.56M0.07$4.60MN/AN/AConduit PharmaceuticalsN/AN/A-$540KN/AN/A Does the MarketBeat Community believe in BON or CDT? Conduit Pharmaceuticals received 1 more outperform votes than Bon Natural Life when rated by MarketBeat users. CompanyUnderperformOutperformBon Natural LifeN/AN/AConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Which has more risk and volatility, BON or CDT? Bon Natural Life has a beta of -1.05, suggesting that its stock price is 205% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Do insiders & institutionals have more ownership in BON or CDT? 0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by company insiders. Comparatively, 34.7% of Conduit Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is BON or CDT more profitable? Company Net Margins Return on Equity Return on Assets Bon Natural LifeN/A N/A N/A Conduit Pharmaceuticals N/A N/A -328.67% SummaryConduit Pharmaceuticals beats Bon Natural Life on 8 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$1.73M$378.07M$8.38B$19.19BDividend YieldN/AN/A2.84%3.62%P/E RatioN/A32.5918.3341.30Price / Sales0.076.0815.5017.51Price / Cash0.3210.6633.4521.28Price / Book0.051.885.565.32Net Income$4.60M-$50.37M$267.23M$989.88M7 Day Performance-13.53%-3.56%-1.89%-3.54%1 Month Performance-6.37%-7.06%-0.91%-4.73%1 Year Performance-74.21%-8.73%10.15%11.57% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.47+1.2%N/A-74.7%$1.73M$25.56M0.00100Gap UpCDTConduit PharmaceuticalsN/A$0.08-4.8%N/A-98.5%$7.98MN/A0.003OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCEROCERo TherapeuticsN/A$0.05-8.1%N/AN/A$7.83MN/A0.008SNGXSoligenix0.7346 of 5 stars$3.12-1.3%N/A-69.6%$7.83M$840,000.00-0.4220Positive NewsGap UpCOEPCoeptis Therapeutics0.3751 of 5 stars$0.19+4.9%N/A-83.9%$7.67M$80,000.00-0.612Gap DownNLSPNLS Pharmaceutics0.364 of 5 stars$1.89-1.0%N/A+336.9%$7.21MN/A0.006News CoverageGap UpEVOKEvoke Pharma0.0363 of 5 stars$4.73+0.4%N/A-63.3%$7.05M$5.18M-0.434News CoverageEYENEyenovia1.4856 of 5 stars$0.08-3.0%$2.00+2,369.1%-94.9%$7.00M$31,832.00-0.1140Gap DownHigh Trading VolumeADILAdial Pharmaceuticals3.3523 of 5 stars$1.09-0.2%$8.00+635.2%-41.8%$6.97MN/A0.0020News CoveragePositive NewsGRIGRI Bio2.5218 of 5 stars0.76-5.0%N/A-97.8%$6.79MN/A0.001 Related Companies and Tools Related Companies Conduit Pharmaceuticals Competitors ObsEva Competitors CERo Therapeutics Competitors Soligenix Competitors Coeptis Therapeutics Competitors NLS Pharmaceutics Competitors Evoke Pharma Competitors Eyenovia Competitors Adial Pharmaceuticals Competitors GRI Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:BON) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
